PolyPid has crossed from a cash-starved Phase 3 developer into a partnered, Priority Review company whose residual value now sits on a single locally delivered antibiotic. D-PLEX100 is a doxycycline-loaded polymer-lipid matrix applied into the surgical wound at closure, designed to hold high local antibiotic concentrations for a month after systemic prophylaxis has washed out. The Food and Drug Administration accepted the new drug application in late July and granted Priority Review, pulling the action date into late November rather than the first quarter of next year. That acceptance also completed the near-term cash from the exclusive Azurity Pharmaceuticals license covering the United States and Canada. The investment case is no longer whether the trial worked. It is whether a clean label and a hospital launch convert a statistically significant infection reduction into recurring royalty and supply income.
Quarter-end cash told a different story from the events that followed. Cash sat at $6.6 million at mid-year. That figure excluded the $30 million of Azurity signing and acceptance payments that closed after the balance-sheet date. Management now describes the post-deal cash as enough to fund operations into 2028, even as the unaudited interim notes still carry substantial-doubt language written before those proceeds landed. The market is being asked to look through a going-concern paragraph at a recapitalized, partnered application. That is a reasonable request only if the Israeli plant inspection and the final label cooperate.
SHIELD II already did the clinical work. In the large-incision cohort the composite of infection, death, and reintervention fell by 38 percent, and the surgical-site infection rate itself fell by more than half versus standard care. What remains is a plant inspection in Israel, a label that has to be usable in the operating room, and a private specialty partner that has never launched this exact product. The next several months resolve whether PolyPid is a royalty-and-supply company or a single-asset developer that peaked at acceptance.